Expert opinion on drug delivery最新文献_第4页

Transfersomes: a next-generation drug delivery system for topical ocular drug delivery. 转移体：用于眼部局部药物传递的下一代药物传递系统。

Expert opinion on drug delivery Pub Date : 2025-05-05 DOI: 10.1080/17425247.2025.2497829

Santosh Bhujbal, Ilva D Rupenthal, Vandana B Patravale, Priyanka Agarwal

{"title":"Transfersomes: a next-generation drug delivery system for topical ocular drug delivery.","authors":"Santosh Bhujbal, Ilva D Rupenthal, Vandana B Patravale, Priyanka Agarwal","doi":"10.1080/17425247.2025.2497829","DOIUrl":"https://doi.org/10.1080/17425247.2025.2497829","url":null,"abstract":"Introduction: The eye is a complex organ with several anatomical and physiological barriers that make ocular drug delivery an ongoing challenge. Transfersomes (TFS) are deformable vesicles that have been extensively applied to enhance transdermal drug delivery. However, their application in ocular drug delivery remains largely unexplored.Areas covered: This review highlights the challenges typically associated with ocular drug delivery and emphasizes the inherent properties of TFS that enable them to overcome these challenges. The influence of excipients and critical process parameters on TFS characteristics have been discussed in detail with an emphasis on the fabrication and characterization techniques typically employed for TFS development and optimization. Furthermore, recent studies evaluating the application of TFS in ocular drug delivery have been discussed in depth.Expert opinion: The unique stress-responsive and deformable nature of TFS makes them promising carriers for ocular drug delivery. However, further research in this direction is needed to understand their penetration mechanism and elucidate their potential for sustained and targeted drug delivery to ocular tissues. Moreover, further research is needed to optimize the stability and scalability of TFS to encourage their translation to the market.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1-22"},"PeriodicalIF":0.0,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A look to the future: cyclodextrins and cyclodextrin-based drug delivery to the retina. 展望未来：环糊精和基于环糊精的视网膜药物输送。

Expert opinion on drug delivery Pub Date : 2025-05-01 Epub Date: 2025-03-20 DOI: 10.1080/17425247.2025.2482049

Phatsawee Jansook, Hákon H Sigurdsson, Thorsteinn Loftsson

{"title":"A look to the future: cyclodextrins and cyclodextrin-based drug delivery to the retina.","authors":"Phatsawee Jansook, Hákon H Sigurdsson, Thorsteinn Loftsson","doi":"10.1080/17425247.2025.2482049","DOIUrl":"10.1080/17425247.2025.2482049","url":null,"abstract":"Introduction: Retinal diseases are a leading cause of vision loss, affecting millions of people worldwide. Current treatment options are based on invasive methods such as intravitreal injections. Therefore, there is a need for alternative therapeutic strategies that are both effective and more patient-friendly.Areas covered: Topical drug delivery has gained attention as a preferred noninvasive approach, although it is hindered by several ocular barriers. Cyclodextrin (CD)-based nanoparticles have emerged as a promising strategy to overcome these limitations by enhancing drug permeability in the posterior segment of the eye. This review discusses the potential of CDs as enabling pharmaceutical excipients, their role in improving ocular drug bioavailability, and provides examples of CD-based eye drop formulations currently under development or undergoing clinical trials. Also, the role of CDs as active pharmaceutical agents in ophthalmology is discussed.Expert opinion: CD-based nanoparticle eye drops present a promising solution and have shown clinical success. CDs are approved pharmaceutical excipients for eye drop formulations and can act as active pharmaceutical ingredients for the treatment of inherent retinal diseases. Future innovations in hybrid CD-based delivery systems and integration of novel therapeutic compounds could provide more efficient and targeted treatment options for retinal diseases.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"693-710"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143660062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The blood-brain barrier as a treatment target for neurodegenerative disorders. 血脑屏障作为神经退行性疾病的治疗靶点。

Expert opinion on drug delivery Pub Date : 2025-05-01 Epub Date: 2025-03-21 DOI: 10.1080/17425247.2025.2480654

Ruslan Rust, Abhay P Sagare, Mingzi Zhang, Berislav V Zlokovic, Kassandra Kisler

{"title":"The blood-brain barrier as a treatment target for neurodegenerative disorders.","authors":"Ruslan Rust, Abhay P Sagare, Mingzi Zhang, Berislav V Zlokovic, Kassandra Kisler","doi":"10.1080/17425247.2025.2480654","DOIUrl":"10.1080/17425247.2025.2480654","url":null,"abstract":"Introduction: The blood-brain barrier (BBB) is a vascular endothelial membrane which restricts entry of toxins, cells, and microorganisms into the brain. At the same time, the BBB supplies the brain with nutrients, key substrates for DNA and RNA synthesis, and regulatory molecules, and removes metabolic waste products from brain to blood. BBB breakdown and/or dysfunction have been shown in neurogenerative disorders including Alzheimer's disease (AD). Current data suggests that these BBB changes may initiate and/or contribute to neuronal, synaptic, and cognitive dysfunction, and possibly other aspects of neurodegenerative processes.Areas covered: We first briefly review recent studies uncovering molecular composition of brain microvasculature and examine the BBB as a possible therapeutic target in neurodegenerative disorders with a focus on AD. Current strategies aimed at protecting and/or restoring altered BBB functions are considered. The relevance of BBB-directed approaches to improve neuronal and synaptic function, and to slow progression of neurodegenerative processes are also discussed. Lastly, we review recent advancements in drug delivery across the BBB.Expert opinion: BBB breakdown and/or dysfunction can significantly affect neuronal and synaptic function and neurodegenerative processes. More attention should focus on therapeutics to preserve or restore BBB functions when considering treatments of neurodegenerative diseases and AD.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"673-692"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143652810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current insights into drug-coated balloons for peripheral arterial disease. 药物包被球囊治疗外周动脉疾病的最新进展。

Expert opinion on drug delivery Pub Date : 2025-05-01 Epub Date: 2025-03-12 DOI: 10.1080/17425247.2025.2476043

Antonio Micari, Antonino Micari, Vittorio Virga, Francesco Costa, Gianluca Di Bella, Giuseppe Roscitano, Antonio Versace, Giuseppe Vadalà, Giampiero Vizzari

{"title":"Current insights into drug-coated balloons for peripheral arterial disease.","authors":"Antonio Micari, Antonino Micari, Vittorio Virga, Francesco Costa, Gianluca Di Bella, Giuseppe Roscitano, Antonio Versace, Giuseppe Vadalà, Giampiero Vizzari","doi":"10.1080/17425247.2025.2476043","DOIUrl":"10.1080/17425247.2025.2476043","url":null,"abstract":"Introduction: Peripheral artery disease (PAD) is a manifestation of systemic atherosclerosis. It is often associated with coronary and/or cerebral vascular involvement, leading to a higher risk of cardiovascular and cerebrovascular events, among which myocardial infarction, stroke, and death. Cardiovascular prevention has proven effective in reducing the progression of the disease and early diagnosis leads to more rapid initiation of medical therapy. However, revascularization of the diseased segment represents the only solution in the manifest and symptomatic forms of the disease.Areas covered: Surgical treatment has historically represented the first treatment of PAD, which consists in the creation of bypasses excluding the obstructed segment. Nowadays, endovascular treatment represents in many cases the first line of intervention. Drug-coated balloons are a cornerstone solution for the treatment of peripheral lesions and are supported by multiple trials demonstrating their efficacy and safety.Expert opinion: New devices, such as sirolimus-eluting balloons, and also new eluting technologies will further improve the efficacy and the results of peripheral angioplasty. In the next years, we will experience the routinary use of new techniques currently under study. In this review, we will discuss the role of drug-coated balloons in the treatment of PAD.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"629-637"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular insights into the antineoplastic potential of apigenin and its derivatives: paving the way for nanotherapeutic innovations. 芹菜素及其衍生物抗肿瘤潜能的分子洞察：为纳米治疗创新铺平道路。

Expert opinion on drug delivery Pub Date : 2025-05-01 Epub Date: 2025-03-17 DOI: 10.1080/17425247.2025.2477664

Debasmita Dutta, Ashique Al Hoque, Brahamacharry Paul, Shahnaz Begum, Uday Aditya Sarkar, Biswajit Mukherjee

{"title":"Molecular insights into the antineoplastic potential of apigenin and its derivatives: paving the way for nanotherapeutic innovations.","authors":"Debasmita Dutta, Ashique Al Hoque, Brahamacharry Paul, Shahnaz Begum, Uday Aditya Sarkar, Biswajit Mukherjee","doi":"10.1080/17425247.2025.2477664","DOIUrl":"10.1080/17425247.2025.2477664","url":null,"abstract":"Introduction: Apigenin, a widely distributed bioactive flavonoid, has recently gained excellent attention among researchers as an effective anticancer drug that can alternate cancer-signaling pathways, induce programmed cell death, and reduce tumor growth in various cancer types. Despite its impressive anti-neoplastic activity, high hydrophobicity, and nonspecific biodistribution make apigenin difficult for pharmaceutical applications.Areas covered: We highlighted the therapeutic potential of apigenin and its derivatives in different cancer types, along with their mechanism of action. Nanoengineered drug delivery systems have remarkable applications in minimizing drug degradation and enhancing the therapeutic efficacy of drugs with sustained release, prolonged blood retention time, and reduced off-target toxicities. This review has evaluated and explored the molecular interactions of this novel flavonoid in various cancer signaling pathways to selectively inhibit neoplastic development in multiple cancer types. To ensure the complete coverage of the explored research area, Google Scholar, PubMed, and Web of Science were used to find not only the most relevant but also connected and similar articles.Expert opinion: A comprehensive overview of apigenin nanotherapy in cancer treatment can establish a platform to overcome its difficulties for pharmaceutical applications and efficient clinical translation from bench to bedside.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"639-658"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Polyphosphoester cubosomes: introducing a novel drug delivery system. 多聚磷酸酯立方体：介绍一种新的给药系统。

Expert opinion on drug delivery Pub Date : 2025-05-01 Epub Date: 2025-03-25 DOI: 10.1080/17425247.2025.2484309

Frederik R Wurm

引用次数: 0

Recent advances in optimizing siRNA delivery to hepatocellular carcinoma cells. 优化肝癌细胞 siRNA 传输的最新进展。

Expert opinion on drug delivery Pub Date : 2025-05-01 Epub Date: 2025-03-30 DOI: 10.1080/17425247.2025.2484287

Ralf Weiskirchen, Sabine Weiskirchen, Chiara Grassi, Bruna Scaggiante, Mario Grassi, Domenico Tierno, Alice Biasin, Nhung Hai Truong, Thanh Dang Minh, Maja Cemazar, Giorgia Pastorin, Federica Tonon, Gabriele Grassi

{"title":"Recent advances in optimizing siRNA delivery to hepatocellular carcinoma cells.","authors":"Ralf Weiskirchen, Sabine Weiskirchen, Chiara Grassi, Bruna Scaggiante, Mario Grassi, Domenico Tierno, Alice Biasin, Nhung Hai Truong, Thanh Dang Minh, Maja Cemazar, Giorgia Pastorin, Federica Tonon, Gabriele Grassi","doi":"10.1080/17425247.2025.2484287","DOIUrl":"10.1080/17425247.2025.2484287","url":null,"abstract":"Introduction: Hepatocellularcarcinoma (HCC), the primary form of liver cancer, is the second leading cause of cancer-related deaths worldwide. Current therapies have limited effectiveness, particularly in advanced stages of the disease, highlighting the need for innovative treatment options. Small-interfering RNA(siRNA) molecules show great promise as a therapeutic solution since they can inhibit the expression of genes promoting HCC growth. Their cost-effective synthesis has further encouraged their potential use as novel drugs. However, siRNAs are vulnerable to degradation in biological environments, necessitating protective delivery systems. Additionally, targeted delivery to HCC is critical for optimal efficacy and minimal undesired side effects.Areacovered: This review addresses the challenges associated with the delivery of siRNA toHCC, discussing and focusing on delivery systems based on lipid and polymeric nanoparticles in publications from the past five years.Expert opinion: Future nano particles will need to effectively cross the vessel wall, migrate through the extracellular matrix and finally cross the HCC cell membrane. This may be achieved by optimizing nanoparticle size, the equipment of nanoparticles withHCC targeting moieties and loading nanoparticles with siRNAs againstHCC-specific oncogenes.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"729-745"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in the use of liquid crystalline nanoparticles for non-small cell lung cancer treatment. 利用液晶纳米粒子治疗非小细胞肺癌的最新进展。

Expert opinion on drug delivery Pub Date : 2025-05-01 Epub Date: 2025-03-07 DOI: 10.1080/17425247.2025.2474693

Thiagarajan Madheswaran, Dinesh Kumar Chellappan, Fiona Sze Nee Lye, Kamal Dua

{"title":"Recent advances in the use of liquid crystalline nanoparticles for non-small cell lung cancer treatment.","authors":"Thiagarajan Madheswaran, Dinesh Kumar Chellappan, Fiona Sze Nee Lye, Kamal Dua","doi":"10.1080/17425247.2025.2474693","DOIUrl":"10.1080/17425247.2025.2474693","url":null,"abstract":"Introduction: Non-small cell lung cancer (NSCLC) continues to pose a considerable health challenge with few therapeutic alternatives. Liquid crystalline nanoparticles (LCN) are nanostructured drug delivery systems made of lipid-based amphiphilic materials that self-assemble into crystalline phases in aqueous environments. LCN have become a promising way to treat NSCLC owing to their specific properties that make them useful for targeted delivery and controlled drug release.Areas covered: The review provides a brief overview of the use of LCN in the treatment of NSCLC. It explores their composition, fabrication methods, and characterization processes. The article further addresses several nanoparticle-based approaches for the treatment of NSCLC. Ultimately, it underscores the promise of LCNs as a promising drug delivery system for NSCLC and discusses the obstacles and outlook in this field.Expert opinion: LCN represents a promising frontier in the treatment of NSCLC, offering several specific advantages over conventional therapies. Utilizing their intrinsic self-assembly characteristics, LCN provides meticulous control over drug encapsulation, release kinetics, and cellular absorption, which are crucial for improving therapy success. LCN also has the capability for co-delivery of various drugs, facilitating synergistic therapeutic benefits and addressing multidrug resistance, a prevalent issue in NSCLC treatment.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"615-627"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143532265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of oral bioavailability enhancement through self-emulsifying drug delivery systems. 通过自乳化给药系统提高口服生物利用度的综述。

Expert opinion on drug delivery Pub Date : 2025-05-01 Epub Date: 2025-03-19 DOI: 10.1080/17425247.2025.2479759

Flavia Laffleur, Gioconda Millotti, Jennifer Lagast

{"title":"An overview of oral bioavailability enhancement through self-emulsifying drug delivery systems.","authors":"Flavia Laffleur, Gioconda Millotti, Jennifer Lagast","doi":"10.1080/17425247.2025.2479759","DOIUrl":"10.1080/17425247.2025.2479759","url":null,"abstract":"Introduction: The pharmaceutical technologists face a lot of challenges and limitations when designing novel drug delivery systems such as low oral bioavailability of many drugs, primarily due to poor solubility, slow dissolution rates, limited permeability through gastrointestinal mucosa, and rapid degradation within the body.Areas covered: The biopharmaceutical classification (BCS) classification represents a map in drug delivery research. Numerous active ingredients are characterized by low bioavailability due to poor water solubility, especially active ingredients of BCS class II and IV. Self-emulsifying drug delivery systems (SEDDS) could act as game changer in order to overcome the challenges and limitations of poor bioavailability. In this review, timelines representing the launch of self-emulsifying drug delivery systems, their introduction to the pharmaceutical platform and their benefits will be discussed in detail.Expert opinion: The development of multifunctional systems capable of combining controlled release, targeted delivery, and diagnostic capabilities is a promising avenue. As the technology matures, self-microemulsifying drug delivery systems and self-nanoemulsifying drug delivery systems are likely to become a standard approach for delivering BCS class II and IV drugs, transforming the pharmaceutical landscape.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"659-671"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Performance characterization of spring-actuated prefilled pen devices for lebrikizumab and dupilumab. 用于lebrikizumab和dupilumab的弹簧驱动预填充笔装置的性能表征。

Expert opinion on drug delivery Pub Date : 2025-05-01 Epub Date: 2025-03-13 DOI: 10.1080/17425247.2025.2477656

Rozhin Derakhshandeh, Javad Eshraghi, Milad Tavakolian, Kevin H Duffy, Jean-Christophe Veilleux, Galen H Shi, Pavlos P Vlachos

{"title":"Performance characterization of spring-actuated prefilled pen devices for lebrikizumab and dupilumab.","authors":"Rozhin Derakhshandeh, Javad Eshraghi, Milad Tavakolian, Kevin H Duffy, Jean-Christophe Veilleux, Galen H Shi, Pavlos P Vlachos","doi":"10.1080/17425247.2025.2477656","DOIUrl":"10.1080/17425247.2025.2477656","url":null,"abstract":"Background: Design parameters of prefilled pens, known as autoinjectors within the medical device community, can affect pen's functioning and user experience. This study compares the performance of two 2 mL prefilled pen devices: lebrikizumab (125 mg/mL) and dupilumab (150 mg/mL).Research design and methods: We recorded force and acoustic signals during administration from the prefilled pen devices and performed high-speed video recording during needle insertion and drug delivery. Measurements were reported in these categories: (i) The kinematics of needle movement during insertion captured by two cameras (ii) Injection flow rate and duration, and the time between acoustic 1st (activation) click and 2nd click sounds (iii) Post-2nd click injection duration, and (iv) delivered dose volume. We investigated the impact of temperature on device performance by experimenting at room temperature (~25℃) and cool condition (~5℃).Results: The lebrikizumab device demonstrated faster injection and more reliable end-of-dose indication, while the dupilumab device showed less lateral needle movement in air during insertion. The device activation forces are provided.Conclusion: Our investigation uncovered performance distinctions between lebrikizumab and dupilumab prefilled pens, which could potentially translate into patient experience, and varying levels of risk associated with intramuscular injection for the adult population and premature device removal.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"747-756"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0